Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects
Titel:
Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects
Auteur:
Liu, Long Qi, Lu Lei, Chunpu Wang, Yu Zhang, Wei Liu, Ying Li, Pu Bai, Haihong Li, Yan Li, Yinjuan Liu, Ju Xie, Liangzhi Wang, Xinghe